Merck

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Merck 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About MRK

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. 

CEO
Robert M. Davis
CEORobert M. Davis
Employees
75,000
Employees75,000
Headquarters
Rahway, New Jersey
HeadquartersRahway, New Jersey
Founded
1891
Founded1891
Employees
75,000
Employees75,000

MRK Key Statistics

Market cap
356.04B
Market cap356.04B
Price-Earnings ratio
115.34
Price-Earnings ratio115.34
Dividend yield
2.36%
Dividend yield2.36%
Average volume
9.11M
Average volume9.11M
High today
$145.44
High today$145.44
Low today
$142.73
Low today$142.73
Open price
$143.77
Open price$143.77
Volume
9.66M
Volume9.66M
52 Week high
$156.92
52 Week high$156.92
52 Week low
$82.01
52 Week low$82.01

Stock Snapshot

With a market cap of 356.04B, Merck(MRK) trades at $144.07. The stock has a price-to-earnings ratio of 115.34 and currently yields dividends of 2.36%.

On 2026-10-04, Merck(MRK) stock traded between a low of $142.73 and a high of $145.44. Shares are currently priced at $144.07, which is +0.9% above the low and -0.9% below the high.

Merck(MRK) shares are trading with a volume of 9.66M, against a daily average of 9.11M.

During the past year, Merck(MRK) stock moved between $82.01 at its lowest and $156.92 at its peak.

During the past year, Merck(MRK) stock moved between $82.01 at its lowest and $156.92 at its peak.

MRK News

TipRanks 2d
Shattuck Labs price target raised to $14 from $11 at Wedbush

Wedbush analyst David Nierengarten raised the firm’s price target on Shattuck Labs (STTK) to $14 from $11 and keeps an Outperform rating on the shares. The firm...

Simply Wall St 2d
Merck Advances Tulisokibart After Positive Phase 2b Hidradenitis Suppurativa Data

Merck (NYSE:MRK) reported positive Phase 2b data for tulisokibart in moderate to severe hidradenitis suppurativa patients. The trial showed both medium and hig...

Merck Advances Tulisokibart After Positive Phase 2b Hidradenitis Suppurativa Data
24/7 Wall St. 3d
JNJ or MRK: One Dividend Is Built to Last, One Faces a Reckoning

Investing JNJ or MRK: One Dividend Is Built to Last, One Faces a Reckoning Both JNJ and MRK have surged in 2026, but a looming patent cliff and a balance sheet...

JNJ or MRK: One Dividend Is Built to Last, One Faces a Reckoning

Analyst ratings

68%

of 31 ratings
Buy
67.7%
Hold
29%
Sell
3.2%

More MRK News

TipRanks 3d
Merck: Emerging Immunology Strength and HS Execution Support Unchanged $160 Price Target and Buy Rating

Merck & Company, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Asad Haider from Goldman Sachs maintained a Buy rating...

Investor's Business Daily 3d
Moderna Soars On Cancer Vaccine. Is mRNA Ready For Prime Time? - Investor's Business Daily

...

Moderna Soars On Cancer Vaccine. Is mRNA Ready For Prime Time? - Investor's Business Daily
TipRanks 3d
Spyre Therapeutics price target raised to $130 from $121 at Jones

Jones analyst Debanjana Chatterjee raised the firm’s price target on Spyre Therapeutics (SYRE) to $130 from $121 and keeps a Buy rating on the shares. The firm...

Simply Wall St 4d
Merck Stock Still Looks Reasonable On Its 110% Run

shares have climbed sharply in recent years, so the live question is whether the current price is still in line with the cash the business is expected to genera...

Merck Stock Still Looks Reasonable On Its 110% Run
Zacks 4d
Why Merck Dipped More Than Broader Market Today

In the latest close session, Merck (MRK Quick QuoteMRK - Free Report) was down 2.66% at $145.31. The stock fell short of the S&P 500, which registered a l...

Why Merck Dipped More Than Broader Market Today
Benzinga 4d
Merck Says Investigational Skin Therapy Shows Potential

Merck & Co Inc. (NYSE:MRK) on Wednesday presented initial results from its Phase 2b MK-7240-012 trial at the European Academy of Dermatology and Venereology (EA...

Merck Says Investigational Skin Therapy Shows Potential
Seeking Alpha 4d
Merck succeeds in mid-stage trial for skin disease drug

Merck (MRK) on Wednesday announced that it succeeded in a mid-stage trial for tulisokibart, its experimental therapy for an inflammatory skin condition known as...

Merck succeeds in mid-stage trial for skin disease drug

People also own

Based on the portfolios of people who own MRK. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.